Real Time Insider Transaction Data
Real Time Insider buys and sells Data - Insider Trades - Insider Transactions - Insider Trading Data - SEC Form 4 Data
Total | Transactions | Amount |
Buys | 0 | $0 |
Sells | 66 | $8,320,822 |
Security | Reporting Name | Relationship | Purchase/Sale | Shares | Price $ | D/I | ||||
05 Mar 2025 16:22 | ALNY | ALNYLAM PHARMACEUTICALS Inc | FITZGERALD KEVIN JOSEPH | CSO & EVP, Head of Research | 03 Mar 2025 | Sale | 204 | 242.37 | 49,443 | D |
05 Mar 2025 16:22 | ALNY | ALNYLAM PHARMACEUTICALS Inc | FITZGERALD KEVIN JOSEPH | CSO & EVP, Head of Research | 03 Mar 2025 | Sale | 224 | 243.36 | 54,513 | D |
05 Mar 2025 16:22 | ALNY | ALNYLAM PHARMACEUTICALS Inc | FITZGERALD KEVIN JOSEPH | CSO & EVP, Head of Research | 03 Mar 2025 | Sale | 151 | 244.41 | 36,906 | D |
05 Mar 2025 16:22 | ALNY | ALNYLAM PHARMACEUTICALS Inc | FITZGERALD KEVIN JOSEPH | CSO & EVP, Head of Research | 03 Mar 2025 | Sale | 111 | 245.26 | 27,224 | D |
05 Mar 2025 16:22 | ALNY | ALNYLAM PHARMACEUTICALS Inc | FITZGERALD KEVIN JOSEPH | CSO & EVP, Head of Research | 03 Mar 2025 | Sale | 45 | 246.18 | 11,078 | D |
05 Mar 2025 16:22 | ALNY | ALNYLAM PHARMACEUTICALS Inc | FITZGERALD KEVIN JOSEPH | CSO & EVP, Head of Research | 03 Mar 2025 | Sale | 4 | 247.35 | 989 | D |
05 Mar 2025 16:22 | ALNY | ALNYLAM PHARMACEUTICALS Inc | FITZGERALD KEVIN JOSEPH | CSO & EVP, Head of Research | 03 Mar 2025 | Sale | 1 | 248.36 | 248 | D |
05 Mar 2025 16:22 | ALNY | ALNYLAM PHARMACEUTICALS Inc | FITZGERALD KEVIN JOSEPH | CSO & EVP, Head of Research | 03 Mar 2025 | Sale | 465 | 242.69 | 112,851 | D |
05 Mar 2025 16:22 | ALNY | ALNYLAM PHARMACEUTICALS Inc | FITZGERALD KEVIN JOSEPH | CSO & EVP, Head of Research | 03 Mar 2025 | Sale | 487 | 243.94 | 118,799 | D |
05 Mar 2025 16:22 | ALNY | ALNYLAM PHARMACEUTICALS Inc | FITZGERALD KEVIN JOSEPH | CSO & EVP, Head of Research | 03 Mar 2025 | Sale | 219 | 245.3 | 53,721 | D |
05 Mar 2025 16:22 | ALNY | ALNYLAM PHARMACEUTICALS Inc | FITZGERALD KEVIN JOSEPH | CSO & EVP, Head of Research | 04 Mar 2025 | Sale | 121 | 239.24 | 28,948 | D |
05 Mar 2025 16:22 | ALNY | ALNYLAM PHARMACEUTICALS Inc | FITZGERALD KEVIN JOSEPH | CSO & EVP, Head of Research | 04 Mar 2025 | Sale | 328 | 240.95 | 79,032 | D |
05 Mar 2025 16:22 | ALNY | ALNYLAM PHARMACEUTICALS Inc | FITZGERALD KEVIN JOSEPH | CSO & EVP, Head of Research | 04 Mar 2025 | Sale | 324 | 241.68 | 78,304 | D |
05 Mar 2025 16:22 | ALNY | ALNYLAM PHARMACEUTICALS Inc | FITZGERALD KEVIN JOSEPH | CSO & EVP, Head of Research | 04 Mar 2025 | Sale | 71 | 242.93 | 17,248 | D |
03 Mar 2025 16:30 | ALNY | ALNYLAM PHARMACEUTICALS Inc | FITZGERALD KEVIN JOSEPH | CSO & EVP, Head of Research | 28 Feb 2025 | Sale | 27 | 236.51 | 6,386 | D |
03 Mar 2025 16:30 | ALNY | ALNYLAM PHARMACEUTICALS Inc | FITZGERALD KEVIN JOSEPH | CSO & EVP, Head of Research | 28 Feb 2025 | Sale | 21 | 238.33 | 5,005 | D |
03 Mar 2025 16:30 | ALNY | ALNYLAM PHARMACEUTICALS Inc | FITZGERALD KEVIN JOSEPH | CSO & EVP, Head of Research | 28 Feb 2025 | Sale | 22 | 239.18 | 5,262 | D |
03 Mar 2025 16:30 | ALNY | ALNYLAM PHARMACEUTICALS Inc | FITZGERALD KEVIN JOSEPH | CSO & EVP, Head of Research | 28 Feb 2025 | Sale | 48 | 240.32 | 11,535 | D |
03 Mar 2025 16:30 | ALNY | ALNYLAM PHARMACEUTICALS Inc | FITZGERALD KEVIN JOSEPH | CSO & EVP, Head of Research | 28 Feb 2025 | Sale | 79 | 241.51 | 19,079 | D |
03 Mar 2025 16:30 | ALNY | ALNYLAM PHARMACEUTICALS Inc | FITZGERALD KEVIN JOSEPH | CSO & EVP, Head of Research | 28 Feb 2025 | Sale | 187 | 242.44 | 45,336 | D |
03 Mar 2025 16:30 | ALNY | ALNYLAM PHARMACEUTICALS Inc | FITZGERALD KEVIN JOSEPH | CSO & EVP, Head of Research | 28 Feb 2025 | Sale | 75 | 243.23 | 18,242 | D |
03 Mar 2025 16:30 | ALNY | ALNYLAM PHARMACEUTICALS Inc | FITZGERALD KEVIN JOSEPH | CSO & EVP, Head of Research | 28 Feb 2025 | Sale | 37 | 244.11 | 9,032 | D |
18 Feb 2025 16:47 | ALNY | ALNYLAM PHARMACEUTICALS Inc | FITZGERALD KEVIN JOSEPH | CSO & EVP, Head of Research | 14 Feb 2025 | Sale | 145 | 252.5 | 36,612 | D |
18 Feb 2025 16:47 | ALNY | ALNYLAM PHARMACEUTICALS Inc | FITZGERALD KEVIN JOSEPH | CSO & EVP, Head of Research | 14 Feb 2025 | Sale | 164 | 253.37 | 41,553 | D |
18 Feb 2025 16:47 | ALNY | ALNYLAM PHARMACEUTICALS Inc | FITZGERALD KEVIN JOSEPH | CSO & EVP, Head of Research | 14 Feb 2025 | Sale | 110 | 254.35 | 27,978 | D |
18 Feb 2025 16:47 | ALNY | ALNYLAM PHARMACEUTICALS Inc | FITZGERALD KEVIN JOSEPH | CSO & EVP, Head of Research | 14 Feb 2025 | Sale | 47 | 255.56 | 12,011 | D |
18 Feb 2025 16:47 | ALNY | ALNYLAM PHARMACEUTICALS Inc | FITZGERALD KEVIN JOSEPH | CSO & EVP, Head of Research | 14 Feb 2025 | Sale | 53 | 256.29 | 13,583 | D |
18 Feb 2025 16:47 | ALNY | ALNYLAM PHARMACEUTICALS Inc | FITZGERALD KEVIN JOSEPH | CSO & EVP, Head of Research | 14 Feb 2025 | Sale | 26 | 257.51 | 6,695 | D |
18 Feb 2025 16:47 | ALNY | ALNYLAM PHARMACEUTICALS Inc | FITZGERALD KEVIN JOSEPH | CSO & EVP, Head of Research | 14 Feb 2025 | Sale | 33 | 258.07 | 8,516 | D |
18 Feb 2025 16:47 | ALNY | ALNYLAM PHARMACEUTICALS Inc | FITZGERALD KEVIN JOSEPH | CSO & EVP, Head of Research | 14 Feb 2025 | Sale | 12 | 259.72 | 3,117 | D |
18 Feb 2025 16:47 | ALNY | ALNYLAM PHARMACEUTICALS Inc | FITZGERALD KEVIN JOSEPH | CSO & EVP, Head of Research | 14 Feb 2025 | Sale | 21 | 260.57 | 5,472 | D |
18 Feb 2025 16:47 | ALNY | ALNYLAM PHARMACEUTICALS Inc | FITZGERALD KEVIN JOSEPH | CSO & EVP, Head of Research | 14 Feb 2025 | Sale | 26 | 261.45 | 6,798 | D |
18 Feb 2025 16:47 | ALNY | ALNYLAM PHARMACEUTICALS Inc | FITZGERALD KEVIN JOSEPH | CSO & EVP, Head of Research | 14 Feb 2025 | Sale | 12 | 263.33 | 3,160 | D |
18 Feb 2025 16:47 | ALNY | ALNYLAM PHARMACEUTICALS Inc | FITZGERALD KEVIN JOSEPH | CSO & EVP, Head of Research | 14 Feb 2025 | Sale | 14 | 264.87 | 3,708 | D |
18 Feb 2025 16:47 | ALNY | ALNYLAM PHARMACEUTICALS Inc | FITZGERALD KEVIN JOSEPH | CSO & EVP, Head of Research | 18 Feb 2025 | Sale | 1,086 | 250.21 | 271,728 | D |
18 Feb 2025 16:47 | ALNY | ALNYLAM PHARMACEUTICALS Inc | FITZGERALD KEVIN JOSEPH | CSO & EVP, Head of Research | 18 Feb 2025 | Sale | 115 | 251.6 | 28,934 | D |
18 Feb 2025 16:47 | ALNY | ALNYLAM PHARMACEUTICALS Inc | FITZGERALD KEVIN JOSEPH | CSO & EVP, Head of Research | 18 Feb 2025 | Sale | 80 | 256.05 | 20,484 | D |
18 Feb 2025 16:47 | ALNY | ALNYLAM PHARMACEUTICALS Inc | FITZGERALD KEVIN JOSEPH | CSO & EVP, Head of Research | 18 Feb 2025 | Sale | 76 | 257.79 | 19,592 | D |
18 Feb 2025 16:47 | ALNY | ALNYLAM PHARMACEUTICALS Inc | FITZGERALD KEVIN JOSEPH | CSO & EVP, Head of Research | 18 Feb 2025 | Sale | 83 | 259.1 | 21,505 | D |
27 Nov 2024 17:20 | ALNY | ALNYLAM PHARMACEUTICALS Inc | FITZGERALD KEVIN JOSEPH | CSO & EVP, Head of Research | 26 Nov 2024 | Sale | 26 | 247.77 | 6,442 | D |
27 Nov 2024 17:20 | ALNY | ALNYLAM PHARMACEUTICALS Inc | FITZGERALD KEVIN JOSEPH | CSO & EVP, Head of Research | 26 Nov 2024 | Sale | 215 | 249.6 | 53,664 | D |
27 Nov 2024 17:20 | ALNY | ALNYLAM PHARMACEUTICALS Inc | FITZGERALD KEVIN JOSEPH | CSO & EVP, Head of Research | 26 Nov 2024 | Sale | 318 | 250.68 | 79,716 | D |
27 Nov 2024 17:20 | ALNY | ALNYLAM PHARMACEUTICALS Inc | FITZGERALD KEVIN JOSEPH | CSO & EVP, Head of Research | 26 Nov 2024 | Sale | 826 | 251.42 | 207,673 | D |
27 Nov 2024 17:20 | ALNY | ALNYLAM PHARMACEUTICALS Inc | FITZGERALD KEVIN JOSEPH | CSO & EVP, Head of Research | 26 Nov 2024 | Sale | 84 | 252.27 | 21,191 | D |
27 Nov 2024 17:20 | ALNY | ALNYLAM PHARMACEUTICALS Inc | FITZGERALD KEVIN JOSEPH | CSO & EVP, Head of Research | 27 Nov 2024 | Sale | 210 | 250.45 | 52,594 | D |
27 Nov 2024 17:20 | ALNY | ALNYLAM PHARMACEUTICALS Inc | FITZGERALD KEVIN JOSEPH | CSO & EVP, Head of Research | 27 Nov 2024 | Sale | 851 | 251.98 | 214,435 | D |
27 Nov 2024 17:20 | ALNY | ALNYLAM PHARMACEUTICALS Inc | FITZGERALD KEVIN JOSEPH | CSO & EVP, Head of Research | 27 Nov 2024 | Sale | 360 | 253.44 | 91,238 | D |
27 Nov 2024 17:20 | ALNY | ALNYLAM PHARMACEUTICALS Inc | FITZGERALD KEVIN JOSEPH | CSO & EVP, Head of Research | 27 Nov 2024 | Sale | 110 | 254.48 | 27,993 | D |
14 Aug 2024 16:12 | ALNY | ALNYLAM PHARMACEUTICALS Inc | FITZGERALD KEVIN JOSEPH | CSO & EVP, Head of Research | 12 Aug 2024 | Sale | 135 | 274.65 | 37,078 | D |
14 Aug 2024 16:12 | ALNY | ALNYLAM PHARMACEUTICALS Inc | FITZGERALD KEVIN JOSEPH | CSO & EVP, Head of Research | 12 Aug 2024 | Sale | 1,158 | 273.73 | 316,979 | D |
14 Aug 2024 16:12 | ALNY | ALNYLAM PHARMACEUTICALS Inc | FITZGERALD KEVIN JOSEPH | CSO & EVP, Head of Research | 12 Aug 2024 | Sale | 5,736 | 271.32 | 1,556,292 | D |
14 Aug 2024 16:12 | ALNY | ALNYLAM PHARMACEUTICALS Inc | FITZGERALD KEVIN JOSEPH | CSO & EVP, Head of Research | 12 Aug 2024 | Sale | 3,913 | 272.43 | 1,066,019 | D |
14 Aug 2024 16:12 | ALNY | ALNYLAM PHARMACEUTICALS Inc | FITZGERALD KEVIN JOSEPH | CSO & EVP, Head of Research | 12 Aug 2024 | Sale | 9,662 | 270.17 | 2,610,383 | D |
14 Aug 2024 16:12 | ALNY | ALNYLAM PHARMACEUTICALS Inc | FITZGERALD KEVIN JOSEPH | CSO & EVP, Head of Research | 12 Aug 2024 | Sale | 1,421 | 268.66 | 381,766 | D |
26 Jun 2024 16:26 | ALNY | ALNYLAM PHARMACEUTICALS Inc | FITZGERALD KEVIN JOSEPH | CSO & EVP, Head of Research | 25 Jun 2024 | Sale | 125 | 235.19 | 29,399 | D |
26 Jun 2024 16:26 | ALNY | ALNYLAM PHARMACEUTICALS Inc | FITZGERALD KEVIN JOSEPH | CSO & EVP, Head of Research | 25 Jun 2024 | Sale | 138 | 234.66 | 32,383 | D |
26 Jun 2024 16:26 | ALNY | ALNYLAM PHARMACEUTICALS Inc | FITZGERALD KEVIN JOSEPH | CSO & EVP, Head of Research | 25 Jun 2024 | Sale | 86 | 233.53 | 20,084 | D |
26 Jun 2024 16:26 | ALNY | ALNYLAM PHARMACEUTICALS Inc | FITZGERALD KEVIN JOSEPH | CSO & EVP, Head of Research | 25 Jun 2024 | Sale | 161 | 232.54 | 37,439 | D |
26 Jun 2024 16:26 | ALNY | ALNYLAM PHARMACEUTICALS Inc | FITZGERALD KEVIN JOSEPH | CSO & EVP, Head of Research | 25 Jun 2024 | Sale | 74 | 231.59 | 17,138 | D |
26 Jun 2024 16:26 | ALNY | ALNYLAM PHARMACEUTICALS Inc | FITZGERALD KEVIN JOSEPH | CSO & EVP, Head of Research | 25 Jun 2024 | Sale | 227 | 229.93 | 52,194 | D |
26 Jun 2024 16:26 | ALNY | ALNYLAM PHARMACEUTICALS Inc | FITZGERALD KEVIN JOSEPH | CSO & EVP, Head of Research | 25 Jun 2024 | Sale | 198 | 229.06 | 45,354 | D |
26 Jun 2024 16:26 | ALNY | ALNYLAM PHARMACEUTICALS Inc | FITZGERALD KEVIN JOSEPH | CSO & EVP, Head of Research | 25 Jun 2024 | Sale | 96 | 228.3 | 21,917 | D |
26 Jun 2024 16:26 | ALNY | ALNYLAM PHARMACEUTICALS Inc | FITZGERALD KEVIN JOSEPH | CSO & EVP, Head of Research | 25 Jun 2024 | Sale | 26 | 226.82 | 5,897 | D |
26 Jun 2024 16:26 | ALNY | ALNYLAM PHARMACEUTICALS Inc | FITZGERALD KEVIN JOSEPH | CSO & EVP, Head of Research | 25 Jun 2024 | Sale | 13 | 225.55 | 2,932 | D |
26 Jun 2024 16:26 | ALNY | ALNYLAM PHARMACEUTICALS Inc | FITZGERALD KEVIN JOSEPH | CSO & EVP, Head of Research | 25 Jun 2024 | Sale | 9 | 224.17 | 2,018 | D |
26 Jun 2024 16:26 | ALNY | ALNYLAM PHARMACEUTICALS Inc | FITZGERALD KEVIN JOSEPH | CSO & EVP, Head of Research | 25 Jun 2024 | Sale | 45 | 221.71 | 9,977 | D |
* D/I = Direct / Indirect
* 10% = Entity with 10% or higher ownership stake
* A = Amendment Filing (SEC Form 4/A)